文献速递胸部肿瘤头颈与中枢神经肿瘤

Lorlatinib治疗晚期ROS1阳性非小细胞肺癌:多中心开放标签单臂1-2期试验

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
PubMed 文献 · Lancet Oncol · 2019-10-25

该研究纳入69例晚期ROS1阳性NSCLC患者,接受Lorlatinib 100mg每日一次口服。TKI初治患者客观缓解率62%(95%CI 38-82),既往仅克唑替尼治疗患者为35%(21-52);颅内缓解率分别为64%和50%。常见3-4级治疗相关不良事件为高甘油三酯血症(19%)和高胆固醇血症(14%)。

要点

  • Lorlatinib在TKI初治和克唑替尼经治ROS1阳性NSCLC中均显示抗肿瘤活性。
  • 颅内缓解在TKI初治和克唑替尼经治患者中分别达64%和50%。
  • 常见3-4级不良事件为高甘油三酯血症和高胆固醇血症。

核心结论

  • Lorlatinib在晚期ROS1阳性NSCLC中显示临床活性,包括CNS转移和既往克唑替尼治疗患者。
  • 克唑替尼难治患者治疗选择有限,Lorlatinib可能成为重要的后续靶向药物。

研究设计与样本

  • 多中心、开放标签、单臂1-2期试验,全球12个国家28家医院参与。
  • 纳入69例组织学或细胞学确诊的晚期ROS1阳性NSCLC患者,年龄≥18岁,ECOG评分≤2(1期仅≤1),伴或不伴CNS转移。
  • Lorlatinib 100mg每日一次口服,连续21天为一周期,直至疾病进展、不可耐受毒性、撤回知情或死亡。
  • 主要终点为独立中心评估的总体和颅内肿瘤缓解,活性分析集为至少接受一剂Lorlatinib的患者。

主要发现

  • 21例(30%)为TKI初治,40例(58%)既往仅接受克唑替尼作为唯一TKI,8例(12%)既往接受一种非克唑替尼ROS1 TKI或两种及以上ROS1 TKI。
  • TKI初治患者客观缓解率62%(13/21,95%CI 38-82),既往仅克唑替尼治疗患者为35%(14/40,95%CI 21-52)。
  • TKI初治患者颅内缓解率64%(7/11,95%CI 31-89),既往仅克唑替尼治疗患者为50%(12/24,95%CI 29-71)。
  • 常见3-4级治疗相关不良事件为高甘油三酯血症(19%,13/69)和高胆固醇血症(14%,10/69)。
  • 严重治疗相关不良事件发生于7%(5/69)患者,未报告治疗相关死亡。

临床怎么用

  • 对于晚期ROS1阳性NSCLC,包括CNS转移和既往克唑替尼治疗患者,Lorlatinib可作为后续靶向治疗选择。
  • 治疗期间需监测高甘油三酯血症和高胆固醇血症等3-4级不良事件。

局限性

  • 单臂设计,无对照,样本量较小(69例)。
  • 部分亚组样本量有限,如TKI初治颅内缓解仅11例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most known resistance mutations in ALK and ROS1. We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer (NSCLC). METHODS: In this open-label, single-arm, phase 1-2 trial, we enrolled patients (aged ≥18 years) with histologically or cytologically confirmed advanced ROS1-positive NSCLC, with or without CNS metastases, with an Eastern Cooperative Oncology Group performance status of 2 or less (≤1 for phase 1 only) from 28 hospitals in 12 countries worldwide. Lorlatinib 100 mg once daily (escalating doses of 10 mg once daily to 100 mg twice daily in phase 1 only) was given orally in continuous 21-day cycles until investigator-determined disease progression, unacceptable toxicity, withdrawal of consent, or death. The primary endpoint was overall and intracranial tumour response, assessed by independent central review. Activity endpoints were assessed in patients who received at least one dose of lorlatinib. This study is ongoing and is registered with ClinicalTrials.gov, NCT01970865. FINDINGS: Between Jan 22, 2014, and Oct 2, 2016, we assessed 364 patients, of whom 69 with ROS1-positive NSCLC were enrolled. 21 (30%) of 69 patients were TKI-naive, 40 (58%) had previously received crizotinib as their only TKI, and eight (12%) had previously received one non-crizotinib ROS1 TKI or two or more ROS1 TKIs. The estimated median duration of follow-up for response was 21·1 months (IQR 15·2-30·3). 13 (62%; 95% CI 38-82) of 21 TKI-naive patients and 14 (35%; 21-52) of 40 patients previously treated with crizotinib as their only TKI had an objective response. Intracranial responses were achieved in seven (64%; 95% CI 31-89) of 11 TKI-naive patients and 12 (50%; 29-71) of 24 previous crizotinib-only patients. The most common grade 3-4 treatment-related adverse events were hypertriglyceridaemia (13 [19%] of 69 patients) and hypercholesterolaemia (ten [14%]). Serious treatment-related adverse events occurred in five (7%) of 69 patients. No treatment-related deaths were reported. INTERPRETATION: Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with CNS metastases and those previously treated with crizotinib. Because crizotinib-refractory patients have few treatment options, lorlatinib could represent an important next-line targeted agent. FUNDING: Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019. PMID: 31669155. doi:10.1016/S1470-2045(19)30655-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。